Project description:Crude extracellular vesicles (EVs) from eight healthy volunteers were separated into 6 fractions based on their densities by using the iodixanol-based density gradient centrifugation method. To determine the distribution of miRNAs among these fractions, quantities of 93 miRNAs were quantified by the TaqMan real time PCR method using the BioMark HD system (Fluidigm) equipped with 96.96 dynamic array (Fluidigm).
Project description:Crude extracellular vesicles (EVs) from eight healthy volunteers were separated into 6 fractions based on their densities by using the iodixanol-based density gradient centrifugation method. To determine the distribution of miRNAs among these fractions, quantities of 93 miRNAs were quantified by the TaqMan real time PCR method using the BioMark HD system (Fluidigm) equipped with 96.96 dynamic array (Fluidigm). Six samples were fractionated from a crude EVs by density gradient centrifugation. Total of 48 samples were prepared from 8 healthy volunteers. Technical replicate of 4 gave 8 x 6 x 4 x 93 = 17,856 data. As control Tris-HCl EDTA buffer (TE) was used.
Project description:Recent literature has documented the use of microRNAs (miRNAs) from circulating extracellular vesicles (EVs) as biomarkers for a plethora of diseases. The aim of this prospective study was to identify the diagnostic value of plasma EV-miRNAs in sepsis.Sepsis patients and healthy controls were matched for age and gender. EVs were separated from plasma of sepsis patients at admission as well as healthy controls. The expression of EV-miRNAs was evaluated by microarray and qRT-PCR.
Project description:Membrane vesicles released by neoplastic cells into extracellular medium contain potential of carrying arrays of oncogenic molecules including proteins and microRNAs (miRNA). Extracellular (exosome-like) vesicles play a major role in cell-to-cell communication. Thus, the characterization of miRNAs of exosome-like vesicles is imperative in clarifying intercellular signaling as well as identifying disease markers. microarray analysis identified several oncogenic miRNA between the two types vesicles.
Project description:MSCs from salivary gland or wharton's jelly were subjected to gene expression analysis, and their extracellular vesicles were used for exosomal miRNA profiling.
Project description:miRNA-sequencing of grapefruit-derived extracellular vesicles and fusion nanovesicles derived from grapefruit-derived extracellular vesicles and gingival mesenchymal stem cell-derived vesicles. We then performed gene expression profiling analysis to explore the miRNAs derived from grapefruit-derived extracellular vesicles, and the retention rate of miRNAs after membrane fusion
Project description:This dataset contains the single-cell gene expression profiles of mouse haematopoietic stem cell and progenitor cell populations isolated by FACS and paired gene expression profiles of their progeny (paired daughter cell assay and paired grand daughter cell assay). Expression of 96 TaqMan probes (A-MTAB-650) was assayed in individual cells by qRT-PCR using 96·96 Dynamic Arrays and the Biomark HD platform (Fluidigm).
Project description:Chronic pelvic pain syndrome (CPPS) and chronic prostatitis (CP) is difficult to distinguish from each other, herein termed CP/CPPS. This study aimed at gaining further insight into the change of extracellular vesicles (EVs) in prostatic fluid of male CPPS. From December 2019 to November 2020, after clinical screening, 24 patients with CPPS without obvious urinary symptoms and 13 healthy male participants were included. EVs were isolated from expressed prostatic secretion (EPS) of all subjects. The small non-coding ribonucleic acid (sncRNA) expression of EVs was sequenced, analysed, and validated by quantitative real-time polymerase chain reaction (qRT-PCR) assays. The results showed that plenty of sncRNAs were differentially expressed between the patients and healthy participants. Further qRT–PCR assays validated that several chronic pain-related miRNAs, including miR-204-5p, let-7d-3p, let-7b-3p, let-7c-3p, miR-146a-5p, and miR-320a-5p, were differentially expressed. Series sncRNAs including several chronic pain-related miRNAs were altered in EVs in prostatic fluid of patients with CPPS, which may serve as diagnostic markers for CPPS.
Project description:Backgroud: Botulinum toxin type A (BTXA) is widely used for the treatment of sialorrhea and other glandular hypersecretion diseases. Micro ribonucleic acid (miRNA) plays an important role in the occurrence and development of salivary diseases, but it is still unclear which role miRNA plays during the inhibition of salivary secretion triggered by BTXA. This work was aimed to explore the miRNA-mRNA expression profiles and functional network after injection of BTXA into submandibular gland. Methods: The differentially expressed (DE) miRNAs and mRNAs between the control group and BTXA group were identified through high-throughput sequencing and bioinformatic analyses and were confirmed by qRT-PCR. Bioinformatic analyses were performed to identify the critical biological functions and signalling pathways and established the functional network. Results: A total of 19 DE miRNAs and 1072 DE mRNAs were identified between the control group and BTXA group. We confirmed 6 DE miRNAs through the qRT-PCR validation. Bioinformatic analysis identified that several pathways may be associated with the inhibition of salivary secretion, such as MAPK signaling pathway, Tight junction and Cytokine-cytokine receptor interaction. We predicted the target genes of these 6 DE miRNAs and established the miRNA-mRNA interaction network. The intersection of DE mRNAs and target genes was performed and finally obtained 7 mRNAs: EGR2, PAQR9, ZKSCAN1, USP6N, lCYB561A3, ZFHX4 and CLIC5. Conclusions: Our study describes the miRNA and mRNA expression profiles and functional network after injection of BTXA into submandibular gland. These findings explore the mechanism of BTXA in inhibiting salivary secretion, and probably provide a new idea for the clinical application. Key words: miRNA-mRNA, BTXA, submandibular gland